DescriptionSources: http://www.drugbank.ca/drugs/DB06825Curator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020715s024,021288s021,022437s002lbl.pdf
Sources: http://www.drugbank.ca/drugs/DB06825
Curator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020715s024,021288s021,022437s002lbl.pdf
Triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). It works by decreasing the production of certain hormones, which reduces testosterone levels in the body. Animal studies comparing triptorelin to native GnRH found that triptorelin had 13 fold higher releasing activity for luteinizing hormone, and 21-fold higher releasing activity for follicle-stimulating hormone. Triptorelin is indicated for the palliative treatment of advanced prostate cancer.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1855 Sources: http://www.drugbank.ca/drugs/DB06825 |
0.3 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | TRELSTAR Approved UseIndicated for the palliative treatment of advanced prostate cancer. Launch Date2000 |
Sample Use Guides
Administered as a single intramuscular injection in either
buttock. Due to different release characteristics, the dosage strengths are not additive and must be selected based upon the desired dosing schedule.
• 3.75 mg every 4 weeks.
• 11.25 mg every 12 weeks
• 22.5 mg every 24 weeks
Route of Administration:
Intramuscular
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22744622
Triptorelin stimulates both oxytocin (OT) and vasopressin (AVP) release from the rat hypothalamo-neurohypophysial (H-N) system at concentrations of 10(-9)-10(-5) M. The strongest effect was displayed by triptorelin at a concentration of 10(-7) M.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1910
Created by
admin on Sat Dec 16 01:19:41 GMT 2023 , Edited by admin on Sat Dec 16 01:19:41 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m11194
Created by
admin on Sat Dec 16 01:19:41 GMT 2023 , Edited by admin on Sat Dec 16 01:19:41 GMT 2023
|
PRIMARY | Merck Index | ||
|
236538
Created by
admin on Sat Dec 16 01:19:41 GMT 2023 , Edited by admin on Sat Dec 16 01:19:41 GMT 2023
|
PRIMARY | RxNorm | ||
|
1696131
Created by
admin on Sat Dec 16 01:19:41 GMT 2023 , Edited by admin on Sat Dec 16 01:19:41 GMT 2023
|
PRIMARY | |||
|
43OFW291R9
Created by
admin on Sat Dec 16 01:19:41 GMT 2023 , Edited by admin on Sat Dec 16 01:19:41 GMT 2023
|
PRIMARY | |||
|
SUB04985MIG
Created by
admin on Sat Dec 16 01:19:41 GMT 2023 , Edited by admin on Sat Dec 16 01:19:41 GMT 2023
|
PRIMARY | |||
|
25080282
Created by
admin on Sat Dec 16 01:19:41 GMT 2023 , Edited by admin on Sat Dec 16 01:19:41 GMT 2023
|
PRIMARY | |||
|
C128693
Created by
admin on Sat Dec 16 01:19:41 GMT 2023 , Edited by admin on Sat Dec 16 01:19:41 GMT 2023
|
PRIMARY | |||
|
140194-24-7
Created by
admin on Sat Dec 16 01:19:41 GMT 2023 , Edited by admin on Sat Dec 16 01:19:41 GMT 2023
|
PRIMARY | |||
|
DBSALT001171
Created by
admin on Sat Dec 16 01:19:41 GMT 2023 , Edited by admin on Sat Dec 16 01:19:41 GMT 2023
|
PRIMARY | |||
|
100000090505
Created by
admin on Sat Dec 16 01:19:41 GMT 2023 , Edited by admin on Sat Dec 16 01:19:41 GMT 2023
|
PRIMARY | |||
|
43OFW291R9
Created by
admin on Sat Dec 16 01:19:41 GMT 2023 , Edited by admin on Sat Dec 16 01:19:41 GMT 2023
|
PRIMARY | |||
|
DTXSID301033427
Created by
admin on Sat Dec 16 01:19:41 GMT 2023 , Edited by admin on Sat Dec 16 01:19:41 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD